CD19 and non-Hodgkin lymphoma: For the treatment of B-lineage-derived cancers, a total of four CD19- and two BCMA-targeted CAR T cell products with distinct biological properties have been approved by the US FDA over the last 5 years since 2017 and have contributed to improved survival in acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, and multiple myeloma [2].